Concepedia

Author

Thomas J. Nevill

University of British ColumbiaORCID

Also Known As

Andrew Turner, Donna Hogge, T J NEVILL, T J Nevill, T Nevill, T. J. Nevill, T. Nevill, T.J. Nevill, Thomas J Nevill, Thomas J. Nevill

187

Publications

4.1K

Citations

32

H-Index

71

Concepts

All Affiliations

University of British ColumbiaBC Cancer AgencyVancouver General HospitalPrincess Margaret Cancer CentreLeukemia & Lymphoma Society of Canada
TJ

About

Thomas J. Nevill is an author at University of British Columbia specializing in medicine, cell transplantation, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

35

2K

2

Health Sciences

9

9

321

3

Blood Transplantation

7

7

521

4

Engineering

1

1

11

5

Biostatistics

1

1

32

Thomas J. Nevill

×

64

Publications

3.9K

Citations

32

H-Index

YearCitations

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn L. Slovak,

Blood

2013

621

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Irwin Walker, Tony Panzarella, Stephen Couban,

The Lancet Oncology

2015

354

Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.

Stephen H. Petersdorf, Kenneth J. Kopecky, Robert K. Stuart,

Blood

2009

182

Donor leukocyte infusions for multiple myeloma

Thomas J. Nevill, Deborah Marcellus, Pablo Parker,

Bone Marrow Transplantation

2000

178

Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation

Thomas J. Nevill, Henry C. Fung, John D. Shepherd,

Blood

1998

161

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver

Julye C. Lavoie, Joseph M. Connors, Gordon L. Phillips,

Blood

2005

121

Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia

Matthew Greenwood, Matthew D. Seftel, C G Richardson,

Leukemia & lymphoma/Leukemia and lymphoma

2006

106

Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an <scp>MDS</scp>‐<scp>CAN</scp> prospective study

Rena Buckstein, Richard A. Wells, Nancy Zhu,

British Journal of Haematology

2016

96

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells

Amina Kariminia, Shernan G. Holtan, Sabine Ivison,

Blood

2016

91

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Irwin Walker, Tony Panzarella, Stephen Couban,

The Lancet Haematology

2020

91

Page 1